Uncommon Syndromes and Treatment Manifestations of Malignancy-Reference-Cited by-同舟云学术

Uncommon Syndromes and Treatment Manifestations of Malignancy

Published:2003-01-01 Issue:1 Volume:21 Page:172-173
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Ramar Kannan¹,Potti Anil¹,Mehdi Syed A.¹

Affiliation:

1. Department of Medicine and Division of Oncology, University of North Dakota School of Medicine; and the Division of Oncology, VA Medical Center, Fargo, ND

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2003.01.052

Reference6 articles.

1. Chronic Myeloid Leukemia

2. Ottmann OG, Sawyers CL, Druker B, et al: A phase 2 study to determine the safety and anti-leukemic effects of STI 571 in adult patients with Philadelphia chromosome positive acute leukemias. Blood 96:828a,2000,

3. Imatinib Mesylate — A New Oral Targeted Therapy

4. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

5. Sawyers C, Hochhaus A, Feldman E, et al: A phase 2 study to determine the safety and anti-leukemic effects of STI 571 in patients with Philadelphia chromosome positive CML in myeloid blast crisis. Blood 96:470a,2000,

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leucémies chroniques;Pharmacie Clinique Pratique en Oncologie;2020

2. Chronic Myeloid Leukemia (CML);Leukemia and Related Disorders;2011-11-26

3. Uncommon or Delayed Adverse Events Associated With Imatinib Treatment for Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2010-10

4. Management of Drug Toxicities in Chronic Myeloid Leukaemia;Best Practice & Research Clinical Haematology;2009-09

5. Ocular side effects in chronic myeloid leukemia patients treated with imatinib;Leukemia Research;2008-07